Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Mar 2025 According to an Arthrosi Therapeutics media release, company announced the completion of enrollment in this study. and company expects to complete this trial in the first half of 2026.
05 Mar 2025 Status changed from recruiting to active, no longer recruiting, According to an Arthrosi Therapeutics media release.
18 Dec 2024 According to an Arthrosi Therapeutics media release, company shows intention that its pivotal phase 3 program will support a comprehensive New Drug Application to the U.S. Food and Drug Administration in all gout patients.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com